Arthur Hiller

Arthur Hiller is a Boston-based biopharma executive currently serving as interim CEO at Amasa Therapeutics and CartilaGen, biopharmaceutical companies focused, respectively, on the development of novel, stem cell-based, targeted biological therapeutics to treat cancer patients, and on an intra-articular injection to prevent post-traumatic osteoarthritis following traumatic musculoskeletal fractures.  He also provides consulting and business advisory roles at a range of life sciences companies in drug discovery, pharmaceuticals, digital health, synthetic biology, and diagnostic imaging.  

His career spans more than 35 years of experience across a wide range of functional areas and sectors of the life sciences and healthcare technology industry, including senior leadership roles in setting strategy, building Commercial Operations, launching products, new product development, sales management, and corporate development. Over the last decade, he has been full-time CEO of two venture-backed early-stage companies in the areas of drug discovery and cardiovascular medical devices, and Chief Business Officer of an emerging digital health technology company and an AI drug discovery company. 

Earlier in his career, he held executive positions in general management, marketing, sales, sales management, and business development at Millennium Pharmaceuticals, Inc., Merck and Co, and two other large, multinational pharmaceutical companies.  He also served as Senior Vice President, Business Development for Merck-Medco Managed Care, where he focused his efforts on the conceptualization and execution of numerous alliances with pharmaceutical manufacturers to support and expand Merck-Medco disease management programs.  

Arthur holds a Bachelor’s Degree in journalism from Northwestern University and a Master’s Degree in Business Policy from Columbia University. He has been a Lecturer and faculty member for the MIT Healthcare Ventures class for over a decade, and serves in Advisory Board and mentoring capacities for a wide range of start-up and early stage companies in the Boston area.